The UK government-backed fund has secured commitments from Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda.
Pharmaceutical firms Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda have all committed to a $100m UK-based fund launched today to support the development of novel dementia treatments.
The Dementia Discovery Fund (DDF) will be managed by venture capital firm SV Life Sciences, and also counts the UK government’s Department of Health and medical charity Alzheimer’s Research UK as limited partners.
DDF aims to discover and develop technology over the next 10 years that will improve diagnosis and symptoms…